IFRX - Latest News
InflaRx N.V. (IFRX), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $300.5M. Beta to the broader market is 2.50.
The article list below shows the most recent IFRX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent IFRX Headlines
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
globenewswire.com - Aug 6, 2026
Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned Initiated fe
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
globenewswire.com - Jul 30, 2026
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N. V.
Reviewing InflaRx (NASDAQ:IFRX) and Kamada (NASDAQ:KMDA)
defenseworld.net - Jul 26, 2026
Kamada (NASDAQ: KMDA - Get Free Report) and InflaRx (NASDAQ: IFRX - Get Free Report) are both small-cap medical companies, but which is the better inv
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
globenewswire.com - Jun 30, 2026
Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N. V.
How News Affects IFRX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track IFRX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked IFRX news questions
- What is the latest IFRX news headline?
- The most recent IFRX headline (Aug 6, 2026) is "InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the IFRX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What IFRX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual IFRX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.